Diseases & Disorders
(G800)
IRS Verified
DX Registered
990 on File
JOSLIN DIABETES CENTER INC
Financial strength (30%)
99/100
Reliability (20%)
55/100
Effectiveness (25%)
88/100
Impact (25%)
No data yet
Register and add impact metrics to be rated above three stars
CharityAI™ Score
Not yet evaluated
Mission Statement
Joslin Diabetes Center — dedicated to conquering diabetes in all of its forms — is the global leader in diabetes research, care and education. Joslin research is at the forefront of discovery aimed at preventing and curing diabetes. The Joslin clinic develops innovative patient therapies that immeasurably improve the lives of people with diabetes. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.
Financial Overview — FY 2025
$77.3M
Total Revenue
$88.2M
Total Expenses
$168.7M
Net Assets
499
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
79.7%
Fundraising Efficiency
8.9%
Operating Reserve
22.96x
Liability-to-Asset
7.7%
Revenue Diversification
48.1%
Executive Compensation
$2.8M
Compared with Peers
FY 2025
Compared with 105 similar organizations
(United States, Diseases & Disorders, $10M–$100M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
79.7% | 85.4% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
20.3% | 11.1% |
P10P90
|
Bottom quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 1.0% |
P10P90
|
Above median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
8.9% | 368.9% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
23.0 mo | 10.0 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
7.7% | 23.0% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
48.1% | 92.0% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
7.9% | 7.9% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
8.0% | 7.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-14.1% | 3.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $77.3M | $88.2M | $168.7M | 79.7% | 499 |
| 2024 | $71.6M | $81.6M | $160.6M | 78.7% | 407 |
| 2023 | $74.2M | $82.8M | $154.0M | 81.8% | 550 |
| 2022 | $134.2M | $98.0M | $146.1M | 78.3% | 616 |
| 2021 | $81.8M | $90.4M | N/A | — | 607 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.